Prostate CA Prevention Drug Rejected by FDA Panel
Links shared publicly online about this topic
Medical News: FDA Panel Rejects Prostate Drugs for CA Prevention - in Oncology/Hematology, Prostate Cancer from MedPage Today
medpagetoday.com — “SILVER SPRING, Md. -- An FDA advisory panel has voted overwhelmingly that GlaxoSmithKline's dutasteride (Avodart) and Merck's finasteride (Proscar) should not be used to prevent prostate cancer becaus” View full resource at medpagetoday.com
Most Recently Shared on December 2, 2010 at 12:37 am By:
FDA Panel Rejects Prostate Drugs for CA Prevention http://bit.ly/fgyEA8
FDA Panel Rejects Two Drugs for Prostate Cancer Prevention - AOL Health
aolhealth.com — “A panel of federal health on Wednesday rejected the use of two drugs from Merck and GlaxoSmithKline to prevent prostate cancer, saying the drugs could” View full resource at aolhealth.com
Most Recently Shared on December 3, 2010 at 6:45 pm By:
FDA rejects two drugs for prostate cancer prevention. http://aol.it/gxm8Zg #prostate #cancer
FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention - Renal and Urology News
renalandurologynews.com — “An FDA advisory panel has voted against expanding the labeling of dutasteride (Avodart, GlaxoSmithKline) and finasteride (Proscar, Merck) so that these drugs--"which are indicated for the treatment of benign prostatic hyperplasia (BPH)--"could be marketed for the prevention of prostate cancer (PCa) in men at risk for the disease.” View full resource at renalandurologynews.com
Most Recently Shared on December 3, 2010 at 1:31 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
FDA Panel Rejects Use of BPH Drugs for Prostate Cancer Prevention: An FDA advisory panel has voted against expan... http://bit.ly/dNQ4zo
FDA Panel Reviews BPH Drugs for Reducing Prostate Cancer Risk : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on December 2, 2010 at 1:32 am By:
Bob Finn - Medical News Net Health News
FDA panel doesn't like risk/benefit ratio of finasteride & dutasteride for prostate ca prevention. @elizmech reports. http://bit.ly/hB5rtH
F.D.A. Panel Won--™t Expand Use of Prostate Drug - NYTimes.com
nytimes.com — “If the drug advisory panel had supported the changing of two drugs--™ labels, dutasteride and finasteride would be only the second class of cancer-prevention drugs on the market.” View full resource at nytimes.com
Most Recently Shared on December 2, 2010 at 3:47 am By:
F.D.A. Panel Rejects Expanded Use of Prostate Drug http://nyti.ms/dW8kbd
F.D.A. Panel Won--™t Expand Use of Prostate Drug - NYTimes.com
nytimes.com — “If the drug advisory panel had supported the changing of two drugs--™ labels, dutasteride and finasteride would be only the second class of cancer-prevention drugs on the market.” View full resource at nytimes.com
Most Recently Shared on December 3, 2010 at 12:10 am By:
Men For A Cause (TM) Health Organization
F.D.A. Panel Rejects Expanded Use of Prostate Drug http://ping.fm/YvSrH
F.D.A. Panel Won--™t Expand Use of Prostate Drug - NYTimes.com
nytimes.com — “If the drug advisory panel had supported the changing of two drugs--™ labels, dutasteride and finasteride would be only the second class of cancer-prevention drugs on the market.” View full resource at nytimes.com
Most Recently Shared on December 2, 2010 at 10:27 am By:
HealthTrendster Health Executive
F.D.A. Panel Rejects Expanded Use of Prostate Drug: If the drug advisory panel had supported… http://goo.gl/fb/tyGnD
F.D.A. Panel Won--™t Expand Use of Prostate Drug - NYTimes.com
nytimes.com — “If the drug advisory panel had supported the changing of two drugs--™ labels, dutasteride and finasteride would be only the second class of cancer-prevention drugs on the market.” View full resource at nytimes.com
Most Recently Shared on December 4, 2010 at 3:13 am By:
The Kidney Group Physician Group and Nephrology
FDA Rejects Expanded Use of Prostate Drug for Cancer Prevention. http://www.nytimes.com/2010/12/02/health/policy/02drug.html?_r=1&src=me
F.D.A. Panel Won--™t Expand Use of Prostate Drug - NYTimes.com
nytimes.com — “If the drug advisory panel had supported the changing of two drugs--™ labels, dutasteride and finasteride would be only the second class of cancer-prevention drugs on the market.” View full resource at nytimes.com
Most Recently Shared on December 2, 2010 at 3:44 am By:
F.D.A. Panel Rejects Expanded Use of Prostate Drug: If the drug advisory panel had supported the changing of tw... http://nyti.ms/haNmub
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Medical News
unbiased curator, editor & aggregator of the latest medical and healthcare news and information
-
HealthPop
Write about health, diet, fitness, relationships. Our blog is @Thats_Fit.
-
Renal Urology News
Renal and Urology News reports on clinical news for both nephrologists and urologists.
Advertisement
